Canada Markets close in 54 mins

Small Pharma Inc. (DMT.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4000-0.0100 (-2.44%)
As of 02:51PM EST. Market open.
Sign in to post a message.
  • V
    V
    Will this ever make it back to 70 cents?
  • O
    Olafur
    I just bought a good chunk of shares in Small Pharma adding to my portfolio in the psychedelic field. I am in long, all or nothing.
  • T
    Tyler
    There’s still mega potential here. Very early stages
  • O
    Olafur
    Added 10k Small Pharma shares to portfolio today.
  • C
    CaudHenry
    “ The clinical trials began in January and if successful, the firm hopes to be able to start offering it as a licensed treatment in connection with therapy within six years.”
  • V
    V
    25% drop - no news? Some one is really messing with this stock.
  • i
    i
    See you at 3$+
    Just loaded 4680 shares more to my portfolio
  • C
    Chris
    still has $50M+ in cash? Relatively clean cap table? 86M m. cap? I'll take that bet.
  • C
    Cory
    These are the stocks to be in 😎
  • J
    JUSTIN
    .34 cent gain right back to where we started an hour ago, will be nice to check in around tail end of 2023
  • O
    Olafur
    11/08/21 HC Wainwright & Co. Initiates Coverage On (DMTTF) Buy 2.5
  • G
    Grace
    Oversold big time
  • T
    Travis
    Peter Rands presenting for Small Pharma right now at the Microdose DMT Conference
  • j
    j
    Hey All. Any body still paying attention to this stock. Comments seam to have gone to sleep.
  • V
    V
    DMT has been so inconsistent as of late. Starting to feel like a pendulum.
  • M
    Mike
    anybody here? whats everyones average
  • V
    V
    DMT is a hidden gem waiting to be discovered. One of the better psychedelic companies out there.
  • V
    V
    Any idea why this stock is tanking today? Buying the DIP.
  • M
    Mike
    Rands says that Small Pharma has an extensive patent portfolio, the bulk of which is in tryptamines and psychedelic tryptamines. 26 of their patent applications are related to psychedelic tryptamines. Many are focused on the DMT molecule without any functional changes to it.
    Rands adds that Small Pharma did develop a technology that uses deuterium to change the half-life of the drug and that two of their preclinical compounds are based on that technology platform.

    https://thedalesreport.com/psychedelics/small-pharma-was-established-to-make-medicine-peter-rands-director-and-ceo/
    We’re pleased to welcome to The Dales Report Peter Rands, the Director and CEO of Small Pharma to discuss his company and their focus on DMT.
    We’re pleased to welcome to The Dales Report Peter Rands, the Director and CEO of Small Pharma to discuss his company and their focus on DMT.
    thedalesreport.com